Back to Results

A Phase 3 Randomized, Open-label Study to Evaluate the Efficacy and Safety of Olaparib Alone or in Combination With Bevacizumab Compared to Bevacizumab With 5-FU in Participants with Unresectable or Metastatic Colorectal Cancer who Have not Progressed Following First-line Induction of FOLFOX With Bevacizumab (LYNK-003)

Study category: Cancer

Is this Study for You?

Let's Get Started!

Details
Age

Adult

Phase

III - Research Studies that gather more information about a drug's safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs. These studies typically involve more participants.

Type of Study

Treatment

Locations

Memorial Hospital Central
Memorial Hospital North
Pikes Peak Regional Hospital

Principal Investigator
Robert Hoyer

Robert Hoyer

Study ID

Protocol Number: 19-6513

More information available at ClinicalTrials.gov: NCT04456699

Categories

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers